Lilly Endowment Reports 9.6% Stake in Eli Lilly in Form 13G/A

Executive Summary

On October 19, 2026, Lilly Endowment, Inc. filed Amendment No. 47 to Schedule 13G with the SEC, disclosing its beneficial ownership of 90,066,978 shares of Eli Lilly and Company (LLY) common stock as of September 30, 2026. This position represents approximately 9.6% of the company's outstanding common stock based on 941,357,065 shares outstanding reported as of August 3, 2026.

Key Ownership Details

• Reporting Entity: Lilly Endowment, Inc. (CIK: 0000316011)
• Filer Classification: Private foundation / 501(c)(3) not-for-profit corporation
• Sole Voting Power: 90,066,978 shares
• Shared Voting Power: 0 shares
• Sole Dispositive Power: 90,066,978 shares
• Shared Dispositive Power: 0 shares
• Total Beneficial Ownership: 90,066,978 shares (9.6%)

Market and Trading Impact

This filing represents a routine periodic amendment (Amendment No. 47) filed pursuant to Rule 13d-1(d) by Eli Lilly's founding charitable endowment. Schedule 13G filings signify passive investment intent, meaning there is no active activist or takeover angle. The trading significance is assessed as Low given the long-term, non-disruptive nature of the Endowment's holdings.